The pre-specified secondary outcomes were (1) all cause-mortality and (2) incidence of a cardiovascular composite event outcome that included: first occurrence of acute myocardial infarction, cardiac arrest or ventricular fibrillation, acute stroke, or coronary revascularization, as previously described and validated using validated International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) and 10th Revision, Clinical Modification (ICD-10-CM) and procedure codes 52,53,54
For most people using semaglutide for weight loss, especially those who dont have diabetes, low blood sugar (also called hypoglycemia) is very unlikely
Yes, but long-term use should be monitored by a healthcare professional to assess safety and effectiveness
Weight-Loss Prescription Medication | Wegovy (semaglutide) Injection 2.4 mg
There are a few considerations